News & Milestones
Stingray in the news
Press coverage, grant announcements, and clinical milestones tracking Stingray's progress from discovery to the clinic.
In the news
Featured Coverage
BioNTX Celebrates North Texas Startup ‘Rising Stars’ at Investor Dinner
Dallas Innovates
The future of oncology therapies: Stingray Therapeutics’ immune-boosting breakthrough
Digital Journal
Unboxing Biotech: Stingray Therapeutics with Jon Northrup
Unboxing Biotech - Youtube
Innovative life science hub opens doors of Houston location, welcomes inaugural startups
Innovation Map
4 Houston life science startups secure over $40M in CPRIT funding
Innovation Map
A Phase 1-2 clinical study to evaluate SR-8541A plus balstilimab and botensilimab in MSS CRC patients
CPRIT
$2 Million SBIR direct to phase II award funds therapeutic development and testing at Stingray Therapeutics and TGen
TGen News
Timeline
Clinical and Corporate Milestones
2026
Clinical
Promising early readouts in Phase 1b/2 US combination trial.
Early clinical activity being observed in the current cohort combining Vizenpistat with botensilimab and balstilimab.
2025
Grants
$4M SBIR Bridge Award secured
NIH SBIR award to cover a portion of the MSS CRC trial combining Vizenpistat with botensilimab and balstilimab.
2024
Clinical
first Patient treated in Phase 1b/2 Study of Vizenpistat (SR-8541A) in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
ClinicalTrials.gov ID: NCT06589440
2023
Grants
$14M CPRIT Award Secured
Cancer Prevention and Research Institute of Texas award to cover 2/3rds of MSS CRC trial combining Vizenpistat with botensilimab and balstilimab.
2023
Clinical
First Patient treated in Phase 1 Study of vizenpistat (SR-8541A) in Advanced/Metastatic Solid Tumors
ClinicalTrials.gov ID: NCT06063681
2022
Grants
$2M SBIR Direct-to-phase-iI award secured
NIH SBIR award to cover pre-clinical and IND enabling studies for Vizenpistat